As a reasonable speculation, triggering endogenous IFN-β production via cytosolic DNA sensor would be a potential strategy for treating MS and EAE, while blocking endogenous IFN-β production may exacerbate symptoms of MS and EAE. This evidence concerns the gene IFNB1 and myeloid sarcoma.